Company Filing History:
1 out of 67 
1 out of 11 
1 out of 265 
Years Active: 2019
Title: Helle Kristensen: Innovator in Prostate Cancer Prognosis
Introduction
Helle Kristensen is a notable inventor based in Aarhus V, Denmark. She has made significant contributions to the field of cancer research, particularly in the prognosis of prostate cancer patients. Her innovative approach utilizes microRNA to assess patient outcomes, showcasing her expertise and dedication to improving cancer diagnostics.
Latest Patents
Helle Kristensen holds a patent for a microrna-based method for assessing the prognosis of a prostate cancer patient. This method involves measuring the expression levels of at least two microRNAs selected from a specific group. The expression levels are analyzed in RNA samples obtained from prostate cells, providing critical insights into the patient's prognosis based on changes compared to a reference expression profile. This patent represents a significant advancement in personalized medicine for prostate cancer.
Career Highlights
Throughout her career, Helle has worked with esteemed institutions such as Aarhus Universitet and Region Midtjylland. Her work in these organizations has allowed her to collaborate with other professionals in the field, further enhancing her research and contributions to cancer prognosis.
Collaborations
Helle Kristensen has collaborated with notable colleagues, including Anni Rønfeldt Thomsen and Karina Dalsgaard Sørensen. These partnerships have enriched her research endeavors and fostered a collaborative environment for innovation in cancer diagnostics.
Conclusion
Helle Kristensen's work in developing a microrna-based method for assessing prostate cancer prognosis exemplifies her commitment to advancing medical science. Her contributions are vital in the ongoing fight against cancer, and her innovative spirit continues to inspire future research in this critical area.